Failure and multiple failure for disease modifying antirheumatic drugs in rheumatoid arthritis: Real-life evidence from a tertiary referral center in Italy
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0281213 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Paola Conigliaro und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of "Medicina dei Sistemi", Rheumatology, Allergology and Clinical Immunology, Università di Roma "Tor Vergata", Rome, Italy. Hauptthemen laut MEDLINE: Antirheumatic Agents, Arthritis, Rheumatoid. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Rheumatoid Arthritis (RA) is a chronic inflammatory disease with a heterogeneous treatments’ clinical response. Goals of treatment are remission and low disease activity, which are not achieved in all patients despite the introduction of early treatment and the treat to target strategy.
Objective
To investigate the causes of disease-modifying antirheumatic drugs (DMARDs) discontinuation and treatment failure and multiple failure for inefficacy, and to identify possible failure predictors’ according to RA patient characteristics in a real-world setting.
Methods
718 RA patients were retrospectively evaluated. Conventional synthetic (cs) and biologic (b)DMARDs treatments line/s, effectiveness, and reasons of discontinuations were evaluated. Patients failing to at least two csDMARDs or bDMARDs’ drug for inefficacy were defined “csDMARDs multifailure” and “bDMARDs multifailure”, respectively. Discontinuation of at least two cs- and bDMARDs was termed “global multifailure”.
Results
In total, 1422 csDMARDs and 714 bDMARDs treatment were analysed. Causes of csDMARDs discontinuation were intolerance (21.8%), inefficacy (20.2%), acute adverse reactions (5.3%) and severe infections (0.6%) while csDMARDs multifailure for inefficacy was observed in 5.7% of cases. Reasons of bDMARDs withdrawal were inefficacy (29%), intolerance (10.0%), acute adverse reaction (6.3%) and severe infections (1.5%). Altogether, 8.4% of patients were bDMARDs multifailure for inefficacy while 16.6% were global multifailure. Longstanding disease (≥ 12 months) and smoke habit, resulted as positive predictor of csDMARDs failure (OR 2.6 and OR 2.7, respectively). Thyreopathy was associated with both csDMARDs failure and global multifailure (OR 2.4 and OR 1.8, respectively). Higher prevalence of failure to at least one bDMARDs and global multifailure was detected in female than male (OR 2.3 and OR 2, respectively).
Conclusions
Different causes of drug discontinuation were observed on DMARDs treatments. Demographic and clinical features were identified as possible predictors of both cs- and bDMARDs treatment failure and multiple failure, underlining the need of a more personalized therapeutic approach to achieve treatment targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of "Medicina dei Sistemi", Rheumatology, Allergology and Clinical Immunology, Università di Roma "Tor Vergata", Rome, Italy.
- Institute of Radiology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
ORCID-Profile: Arianna D'Antonio
Zitieren
APA
Conigliaro, P., D'Antonio, A., D'Erme, L., Lavinia Fonti, G., Triggianese, P., Bergamini, A., & Chimenti, M. S. (2023). Failure and multiple failure for disease modifying antirheumatic drugs in rheumatoid arthritis: Real-life evidence from a tertiary referral center in Italy. PLOS ONE. https://doi.org/10.1371/journal.pone.0281213
Vancouver
Conigliaro P, D'Antonio A, D'Erme L, Lavinia Fonti G, Triggianese P, Bergamini A, et al. Failure and multiple failure for disease modifying antirheumatic drugs in rheumatoid arthritis: Real-life evidence from a tertiary referral center in Italy. PLOS ONE. 2023. doi:10.1371/journal.pone.0281213
BibTeX
@article{Conigliaro2023,
author = {Conigliaro, Paola and D'Antonio, Arianna and D'Erme, Luca and Lavinia Fonti, Giulia and Triggianese, Paola and Bergamini, Alberto and Chimenti, Maria Sole},
title = {Failure and multiple failure for disease modifying antirheumatic drugs in rheumatoid arthritis: Real-life evidence from a tertiary referral center in Italy},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0281213}
}
EUVIMED